Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Liabilities and Shareholders Equity (2016 - 2019)

Historic Liabilities and Shareholders Equity for Soleno Therapeutics (SLNO) over the last 7 years, with Q3 2019 value amounting to $28.7 million.

  • Soleno Therapeutics' Liabilities and Shareholders Equity fell 684.29% to $28.7 million in Q3 2019 from the same period last year, while for Dec 2019 it was $101.7 million, marking a year-over-year decrease of 2919.02%. This contributed to the annual value of $43.2 million for FY2018, which is 1058.12% up from last year.
  • Per Soleno Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $28.7 million for Q3 2019, which was down 684.29% from $34.1 million recorded in Q2 2019.
  • Soleno Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $43.2 million during Q4 2018, with a 5-year trough of $5.5 million in Q2 2016.
  • For the 5-year period, Soleno Therapeutics' Liabilities and Shareholders Equity averaged around $23.1 million, with its median value being $28.7 million (2019).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 3688.71% in 2016, then surged by 60122.26% in 2017.
  • Soleno Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $8.2 million in 2015, then plummeted by 32.15% to $5.6 million in 2016, then soared by 601.22% to $39.0 million in 2017, then increased by 10.58% to $43.2 million in 2018, then crashed by 33.43% to $28.7 million in 2019.
  • Its Liabilities and Shareholders Equity was $28.7 million in Q3 2019, compared to $34.1 million in Q2 2019 and $38.9 million in Q1 2019.